Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3, randomized, double-blind study in about 432 Chinese adults with overweight or obesity. Participants will receive either berobenatide injections once monthly or a placebo for a defined period, with safety and weight-related outcomes monitored. Participation requires meeting BMI criteria and at least one weight-related health condition, and prior weight-loss attempts. The trial aims to determine if berobenatide can produce meaningful weight loss and improve related health factors while assessing tolerability. Key exclusion criteria include recent weight changes, certain diabetes conditions, history of specific thyroid cancer syndromes, recent obesity procedures, and pregnancy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults ≥18 years of age.
* BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one of the following weight-related co-morbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2D.
* At least one prior unsuccessful dietary weight-loss attempt.

Exclusion Criteria:

* Significant recent weight change (\>5% within 3 months).
* Type 1 diabetes mellitus.
* History of pancreatitis.
* Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2).
* Recent bariatric surgery or obesity procedures.
* Pregnancy or breastfeeding.

Where it's running

• The Second Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting
• The Second People's Hospital of Hefei
  Hefei, Anhui, China Not yet recruiting
• Peking University People's Hospital
  Beijing, Beijing Municipality, China Not yet recruiting
• Huizhou Central People's Hospital
  Huizhou, Guangdong, China Not yet recruiting
• The Second Affiliated Hospital of Zhengzhou University
  Zhengzhou, Henan, China Not yet recruiting
• Jiangxi Provincial People's Hospital
  Nanchang, Jiangxi, China Not yet recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.